Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT ID: NCT04975997
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
864 participants
INTERVENTIONAL
2022-06-23
2032-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
NCT05896228
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT05527340
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
NCT05392946
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT06785415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms:
* Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd)
* Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd)
Participants in both treatment arms will continue to receive treatment until confirmed progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure accuracy and completeness of the primary endpoint assessment of progression-free survival (PFS), participants who permanently discontinue study treatment for any reason, other than confirmed PD or withdrawal of consent, will continue to be followed for disease assessment.
The study will be conducted in compliance with International Council for Harmonisation (ICH) and Good Clinical Practices (GCPs).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Daratumumab in combination with Iberdomide and dexamethasone - Dose 1
Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Iberdomide
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
Daratumumab in combination with Iberdomide and dexamethasone - Dose 2
Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Iberdomide
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
Daratumumab in combination with Iberdomide and dexamethasone - Dose 3
Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Iberdomide
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
Daratumumab in combination with dexamethasone and bortezomib
Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Bortezomib
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
Dexamethasone
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
Daratumumab
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
Daratumumab
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
Bortezomib
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
Iberdomide
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
Iberdomide
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
Iberdomide
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
Dexamethasone
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
Daratumumab
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received 1 to 2 prior lines of anti-myeloma therapy.
* Must have documented disease progression during or after their last anti-myeloma regimen.
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
Exclusion Criteria
* Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
* Known central nervous system involvement with MM.
* Prior therapy with iberdomide.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 035
Hot Springs, Arkansas, United States
Local Institution - 641
Cerritos, California, United States
Local Institution - 681
Fountain Valley, California, United States
Local Institution - 047
Los Angeles, California, United States
Local Institution - 684
Newport, California, United States
Local Institution - 033
New Haven, Connecticut, United States
Local Institution - 029
Fort Myers, Florida, United States
Local Institution - 693
Ocala, Florida, United States
Local Institution - 028
St. Petersburg, Florida, United States
Local Institution - 045
Tamarac, Florida, United States
Local Institution - 034
West Palm Beach, Florida, United States
Local Institution - 685
Weston, Florida, United States
Local Institution - 018
Atlanta, Georgia, United States
Local Institution - 640
Elk Grove Village, Illinois, United States
Local Institution - 697
Dyer, Indiana, United States
Local Institution - 040
Louisville, Kentucky, United States
Local Institution - 041
Alexandria, Louisiana, United States
Local Institution - 682
Baton Rouge, Louisiana, United States
Local Institution - 027
Baton Rouge, Louisiana, United States
Local Institution - 698
Baltimore, Maryland, United States
Local Institution - 014
Bethesda, Maryland, United States
Local Institution - 688
Columbia, Maryland, United States
Local Institution - 010
Boston, Massachusetts, United States
Local Institution - 009
Worcester, Massachusetts, United States
Local Institution - 645
Burnsville, Minnesota, United States
Local Institution - 031
Kansas City, Missouri, United States
Local Institution - 046
Billings, Montana, United States
Local Institution - 015
Summit, New Jersey, United States
Local Institution - 691
New York, New York, United States
Local Institution - 039
Durham, North Carolina, United States
Local Institution - 038
Cincinnati, Ohio, United States
Local Institution - 037
Cleveland, Ohio, United States
Local Institution - 008
Cleveland, Ohio, United States
Local Institution - 036
Columbus, Ohio, United States
Local Institution - 680
Tulsa, Oklahoma, United States
Local Institution - 043
Portland, Oregon, United States
Local Institution - 030
Chattanooga, Tennessee, United States
Local Institution - 021
Nashville, Tennessee, United States
Local Institution - 687
Austin, Texas, United States
Local Institution - 695
Houston, Texas, United States
Local Institution - 642
Newport News, Virginia, United States
Local Institution - 643
Roanoke, Virginia, United States
Local Institution - 025
Madison, Wisconsin, United States
Local Institution - 080
Ciudad Autanoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 083
Villa Elisa, Buenos Aires, Argentina
Local Institution - 813
Birtinya, Queensland, Australia
Local Institution - 812
Douglas, Queensland, Australia
Local Institution - 803
Adelaide, South Australia, Australia
Local Institution - 806
Bedford Park, South Australia, Australia
Local Institution - 802
Clayton, Victoria, Australia
Local Institution - 809
East Melbourne, Victoria, Australia
Local Institution - 801
Melbourne, Victoria, Australia
Local Institution - 811
Murdoch, Western Australia, Australia
Local Institution - 807
West Perth, Western Australia, Australia
Local Institution - 804
Camperdown, , Australia
Local Institution - 800
Fitzroy, , Australia
Local Institution - 808
Garran, , Australia
Local Institution - 155
Graz, , Austria
Local Institution - 154
Linz, , Austria
Local Institution - 153
Salzburg, , Austria
Local Institution - 156
Sankt Pölten, , Austria
Local Institution - 150
Vienna, , Austria
Local Institution - 151
Vienna, , Austria
Local Institution - 172
Bruges, , Belgium
Local Institution - 174
Brussels, , Belgium
Local Institution - 056
Curitiba, Paraná, Brazil
Local Institution - 050
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 058
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 051
Barretos, São Paulo, Brazil
Local Institution - 054
Jaú, São Paulo, Brazil
Local Institution - 055
São Paulo, São Paulo, Brazil
Local Institution - 053
Rio de Janeiro, , Brazil
Local Institution - 057
São Paulo, , Brazil
Local Institution - 052
São Paulo, , Brazil
Local Institution - 111
Calgary, Alberta, Canada
Local Institution - 103
Edmonton, Alberta, Canada
Local Institution - 112
Surrey, British Columbia, Canada
Local Institution - 104
Saint John, New Brunswick, Canada
Local Institution - 110
St. John's, Newfoundland and Labrador, Canada
Local Institution - 101
Halifax, Nova Scotia, Canada
Local Institution - 109
Ottawa, Quebec, Canada
Local Institution - 108
Québec, Quebec, Canada
Local Institution - 107
Saskatoon, Saskatchewan, Canada
Local Institution - 141
Changsha, Hunan, China
Local Institution - 129
Nanchang, Jiangxi, China
Local Institution - 143
Xi'an, Shaanxi, China
Local Institution - 142
Shanghai, Shanghai Municipality, China
Local Institution - 145
Taiyuan, Shanxi, China
Local Institution - 144
Wenzhou, Zhejiang, China
Local Institution - 140
Beijing, , China
Local Institution - 139
Beijing, , China
Local Institution - 138
Beijing, , China
Local Institution - 126
Changchun, , China
Local Institution - 121
Chaoyang District, , China
Local Institution - 135
Guangzhou, , China
Local Institution - 136
Guangzhou, , China
Local Institution - 128
Hangzhou, , China
Local Institution - 120
Hangzhou, Zhejiang, , China
Local Institution - 127
Harbin, , China
Local Institution - 134
Nanjing, , China
Local Institution - 132
Shanghai, , China
Local Institution - 130
Shanghai, , China
Local Institution - 131
Shenyang, , China
Local Institution - 124
Suzhu, , China
Local Institution - 133
Tianjin, , China
Local Institution - 137
Wuhan, , China
Local Institution - 125
Xi'an, , China
Local Institution - 123
Zhengzhou, , China
Local Institution - 601
Brno, , Czechia
Local Institution - 600
Ostrava-Poruba, , Czechia
Local Institution - 602
Prague, , Czechia
Local Institution - 371
Aalborg, , Denmark
Local Institution - 370
Odense, , Denmark
Local Institution - 372
Roskilde, , Denmark
Local Institution - 231
Turku, Southwest Finland, Finland
Local Institution - 230
Helsinki, , Finland
Local Institution - 232
Oulu, , Finland
Local Institution - 463
Argenteuil, , France
Local Institution - 462
La Roche-sur-Yon, , France
Local Institution - 451
Lille, , France
Local Institution - 458
Nancy, , France
Local Institution - 454
Nantes, , France
Local Institution - 456
Paris, , France
Local Institution - 452
Paris, , France
Local Institution - 464
Pessac, , France
Local Institution - 465
Rouen, , France
Local Institution - 457
Toulouse, , France
Local Institution - 308
Kiel, Schleswig-Holstein, Germany
Local Institution - 301
Frankfurt am Main, , Germany
Local Institution - 300
Hamburg, , Germany
Local Institution - 302
Hamburg, , Germany
Local Institution - 305
Heidelberg, , Germany
Local Institution - 304
Lübeck, , Germany
Local Institution - 573
Pátrai, Achaea, Greece
Local Institution - 574
Pátrai, Achaia, Greece
Local Institution - 571
Athens, , Greece
Local Institution - 572
Thessaloniki, , Greece
Local Institution - 570
Thessaloniki, , Greece
Local Institution - 932
Hyderabad, Andhra Pradesh, India
Local Institution - 930
Bangalore, Karnataka, India
Local Institution - 934
Ernākulam, Kerala, India
Local Institution - 933
Mumbai, Maharashtra, India
Local Institution - 935
Kolkata, West Bengal, India
Local Institution - 931
Puducherry, , India
Local Institution - 752
Cork, , Ireland
Local Institution - 750
Dublin, , Ireland
Local Institution - 751
Galway, , Ireland
Local Institution - 874
Afula, Northern District, Israel
Local Institution - 872
Haifa, , Israel
Local Institution - 871
Jerusalem, , Israel
Local Institution - 870
Tel Aviv, , Israel
Local Institution - 873
Tel Litwinsky, , Israel
Local Institution - 415
Rome, Lazio, Italy
Local Institution - 400
Bologna, , Italy
Local Institution - 408
Catania, , Italy
Local Institution - 414
Genova, , Italy
Local Institution - 404
Milan, , Italy
Local Institution - 410
Novara, , Italy
Local Institution - 412
Pavia, , Italy
Local Institution - 402
Pisa, , Italy
Local Institution - 405
Reggio Calabria, , Italy
Local Institution - 401
Roma, , Italy
Local Institution - 403
San Giovanni Rotondo FG, , Italy
Local Institution - 406
Udine, , Italy
Local Institution - 900
Matsuyama, Ehime, Japan
Local Institution - 917
Higashi-Ibaraki-gun, Ibaraki, Japan
Local Institution - 919
Shimotsuga, Tochigi, Japan
Local Institution - 920
Nerima-ku, Tokyo, Japan
Local Institution - 918
Shinagawa-ku, Tokyo, Japan
Local Institution - 915
Chuo-shi, Yamanashi, Japan
Local Institution - 912
Aomori, , Japan
Local Institution - 916
Chiba, , Japan
Local Institution - 911
Fukuoka, , Japan
Local Institution - 903
Kamogawa, , Japan
Local Institution - 902
Kyoto, , Japan
Local Institution - 910
Nagoya, , Japan
Local Institution - 901
Nagoya, , Japan
Local Institution - 905
Okayama, , Japan
Local Institution - 907
Osaka, , Japan
Local Institution - 908
Ōsaka-sayama, , Japan
Local Institution - 913
Sapporo, , Japan
Local Institution - 914
Sendai, , Japan
Local Institution - 906
Shibuya-ku, , Japan
Local Institution - 909
Shinagawa-ku, Tokyo, , Japan
Local Institution - 904
Toyohashi, , Japan
Local Institution - 183
Guadalajara, Jalisco, Mexico
Local Institution - 351
Dordrecht, South Holland, Netherlands
Local Institution - 354
Amsterdam, , Netherlands
Local Institution - 352
The Hague, , Netherlands
Local Institution - 202
Bergen, , Norway
Local Institution - 200
Oslo, , Norway
Local Institution - 201
Trondheim, , Norway
Local Institution - 631
Bialystok, Podlaskie Voivodeship, Poland
Local Institution - 633
Krakow, , Poland
Local Institution - 635
Nowy Sącz, , Poland
Local Institution - 634
Poznan, , Poland
Local Institution - 630
Warsaw, , Poland
Local Institution - 636
Wałbrzych, , Poland
Local Institution - 545
Coimbra, , Portugal
Local Institution - 543
Lisbon, , Portugal
Local Institution - 544
Lisbon, , Portugal
Local Institution - 540
Porto, , Portugal
Local Institution - 541
Porto, , Portugal
Local Institution - 974
Daegu, , South Korea
Local Institution - 973
Gyeonggi-do, , South Korea
Local Institution - 975
Hwasun-gun, , South Korea
Local Institution - 971
Seoul, , South Korea
Local Institution - 976
Seoul, , South Korea
Local Institution - 972
Seoul, , South Korea
Local Institution - 970
Seoul, , South Korea
Local Institution - 977
Seoul, , South Korea
Local Institution - 514
Pamplona, Navarre, Spain
Local Institution - 505
Barcelona, , Spain
Local Institution - 502
Barcelona, , Spain
Local Institution - 511
Barcelona, , Spain
Local Institution - 501
Cáceres, , Spain
Local Institution - 509
Córdoba, , Spain
Local Institution - 510
Madrid, , Spain
Local Institution - 516
Madrid, , Spain
Local Institution - 504
Madrid, , Spain
Local Institution - 513
Madrid, , Spain
Local Institution - 503
Málaga, , Spain
Local Institution - 508
Murcia, , Spain
Local Institution - 506
Oviedo, , Spain
Local Institution - 515
Salamanca, , Spain
Local Institution - 500
Santiago de Compostela, , Spain
Local Institution - 512
Valencia, , Spain
Local Institution - 507
Zaragoza, , Spain
Local Institution - 272
Borås, , Sweden
Local Institution - 271
Helsingborg, , Sweden
Local Institution - 851
Chur, , Switzerland
Local Institution - 850
Sankt Gallen, , Switzerland
Local Institution - 955
Niao-Sung Hsiang Kaohsiung County, , Taiwan
Local Institution - 952
Taichung, , Taiwan
Local Institution - 954
Taichung, , Taiwan
Local Institution - 951
Tainan, Taiana, , Taiwan
Local Institution - 950
Taipei, , Taiwan
Local Institution - 956
Taipei, Zhongzheng Dist., , Taiwan
Local Institution - 953
Taoyuan, , Taiwan
Local Institution - 778
Kavaklıdere, Ankara, Turkey (Türkiye)
Local Institution - 776
Yenimahalle, Ankara, Turkey (Türkiye)
Local Institution - 777
Pendik, Istanbul, Turkey (Türkiye)
Local Institution - 771
Balçova, İzmir, Turkey (Türkiye)
Local Institution - 775
Bornova, İzmir, Turkey (Türkiye)
Local Institution - 773
Samsun, Kurupelit, Turkey (Türkiye)
Local Institution - 770
Ankara, , Turkey (Türkiye)
Local Institution - 772
Gaziantep, , Turkey (Türkiye)
Local Institution - 774
Kayseri, , Turkey (Türkiye)
Local Institution - 702
Nottingham, Nottinghamshire, United Kingdom
Local Institution - 705
Belfast Northern Ireland, , United Kingdom
Local Institution - 700
Birmingham, , United Kingdom
Local Institution - 707
Canterbury Kent, , United Kingdom
Local Institution - 704
Lancashire Blackpool, , United Kingdom
Local Institution - 701
London, , United Kingdom
Local Institution - 709
London, , United Kingdom
Local Institution - 706
Oxford, , United Kingdom
Local Institution - 711
Portsmouth, , United Kingdom
Local Institution - 713
Sutton, , United Kingdom
Local Institution - 708
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodriguez-Otero P, Maciag P, Hong K, Amatangelo M, Chen M, van de Donk NWCJ. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025 Jun;21(14):1761-1769. doi: 10.1080/14796694.2025.2501920. Epub 2025 May 10.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1260-2872
Identifier Type: OTHER
Identifier Source: secondary_id
2020-000431-49
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-220-MM-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.